Metronidazol B. Braun (Metronidazole)

Metronidazole enters susceptible anaerobic bacteria and protozoa, where intracellular reduction of its nitro group creates reactive metabolites. These metabolites bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, ultimately leading to cell death.

The dose of Metronidazol B. Braun is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other individual factors. No standard dosing regimen is provided here.

Safety data for Metronidazol B. Braun in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metronidazol B. Braun belongs to the nitroimidazole class, offering rapid bactericidal activity against strict anaerobes and certain protozoa. Compared with beta‑lactam agents, it provides a broader spectrum for anaerobic coverage and does not require beta‑lactamase stability, but selection depends on infection site and susceptibility patterns.

Store Metronidazol B. Braun at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Do not use if the product has been exposed to temperatures outside this range.

Metronidazol B. Braun is administered by intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are set by the prescriber according to the clinical situation and patient tolerance.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, liver toxicity, and neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities during therapy.

Metronidazol B. Braun should be avoided in patients with known hypersensitivity to metronidazole or other nitroimidazoles, in those with severe hepatic impairment unless benefits outweigh risks, and in individuals who have had a disulfiram‑like reaction to alcohol while on therapy.